Longboard Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	175.72	171.02	135.28	135.31
Revenue Growth (YoY)	20.18%	26.42%	-0.03%	-
Cost of Revenue	90.3	86.97	79.46	76.38
Gross Profit	85.42	84.05	55.82	58.93
Selling, General & Admin	112.91	150.74	73.82	75.85
Operating Expenses	115.96	153.86	76.99	78.41
Operating Income	-30.54	-69.81	-21.17	-19.47
Interest Expense	-0.07	-0.09	-0.04	-0.02
Interest & Investment Income	1.61	0.58	0.14	0.3
Other Non Operating Income (Expenses)	-10.85	-2.56	3.19	-0.2
EBT Excluding Unusual Items	-39.85	-71.88	-17.88	-19.4
Gain (Loss) on Sale of Investments	1.13	-0.29	0.05	-0.52
Asset Writedown	-	-	-23.93	-
Pretax Income	-38.72	-72.17	-41.76	-19.92
Income Tax Expense	0	-	0.02	0.02
Net Income	-38.72	-72.17	-41.78	-19.94
Preferred Dividends & Other Adjustments	11.23	8.01	5.79	5.79
Net Income to Common	-49.95	-80.18	-47.57	-25.73
Shares Outstanding (Basic)	42	41	41	82
Shares Outstanding (Diluted)	42	41	41	82
Shares Change (YoY)	36.44%	-	-50.00%	-
EPS (Basic)	-1.19	-1.95	-1.16	-0.31
EPS (Diluted)	-1.19	-1.95	-1.16	-0.31
Free Cash Flow	-62.09	-49.68	-4.75	-13.2
Free Cash Flow Per Share	-1.48	-1.21	-0.12	-0.16
Gross Margin	48.61%	49.15%	41.26%	43.55%
Operating Margin	-17.38%	-40.82%	-15.65%	-14.39%
Profit Margin	-28.43%	-46.88%	-35.16%	-19.01%
Free Cash Flow Margin	-35.34%	-29.05%	-3.51%	-9.76%
EBITDA	-24.43	-63.64	-17.49	-16.91
EBITDA Margin	-13.91%	-37.21%	-12.93%	-12.50%
D&A For EBITDA	6.1	6.17	3.67	2.56
EBIT	-30.54	-69.81	-21.17	-19.47
EBIT Margin	-17.38%	-40.82%	-15.65%	-14.39%
Revenue as Reported	175.72	171.02	135.28	135.31
Advertising Expenses	-	16.87	16.98	29.87

Updated Mar 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q